EMA Panel Recommends Expanded Use for Merck's RSV Treatment Enflonsia in Infants
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use has issued a positive opinion regarding the expanded use of Merck's respiratory syncytial virus (RSV) prevention treatment, Enflonsia (clesrovimab). The recommendation specifically supports using the drug to prevent lower respiratory tract disease caused by RSV in infants. This endorsement marks a significant regulatory milestone for Merck as it seeks to broaden the market application of its RSV preventative therapy. If finalized, this expansion would allow healthcare providers across Europe to utilize Enflonsia more widely within the pediatric population to combat seasonal RSV infections.
Tickers: $MRK
Topics: drug indication expansion EMA approval RSV prevention